Pyxus inks agreement with Turning Point to initiate PMTA submission
Category: #business  By Mateen Dalal  Date: 2020-02-07
  • share
  • Twitter
  • Facebook
  • LinkedIn

Pyxus inks agreement with Turning Point to initiate PMTA submission

Pyxus International, Inc., one of the leading value-added agricultural companies in the world, has reportedly collaborated with Turning Point Brands, a leading company in OTP (Other Tobacco Products) and adult consumer alternatives.

Sources cite that the two companies have agreed to share certain testing data and science-based research to form the foundation of some of their respective PMTAs (Premarket Tobacco Product Applications) before being submitted to U.S. FDA (Food and Drug Administration).

According to reports, Turning Point Brands has inked a supply agreement for its house brands of e-liquids, thereby extending its existing collaboration with Pyxus' joint venture, Purilum, LLC, a manufacturer of high-quality e-liquids, finished bottles, and flavor concentrates products.

Apparently, all tobacco products modified or introduced after Feb. 15, 2007, require premarket permission by the FDA to be commercially marketed in the US. Pursuant to the FDA guidance, all PMTAs are due by 12 May 2020.

Reportedly, both companies will share several costs and key data related to extensive studies conducted to support their PMTAs filings. Additionally, Purilum presently offers the flavor formulations for a few of TPB's innovative products.

Pieter Sikkel, President, CEO and Chairman of Pyxus, said that the company needs likeminded, reputable partners to meet the stringent requirements of the U.S. FDA.

He added that Turning Point Brands, which presently has a strong relationship with the company’s joint venture Purilum, has constantly shown their commitment to quality and compliance. The company is pleased to partner with them to benefit respective PMTAs.

Graham Purdy, COO of Turning Point Brands, said that Purilum has garnered a reputation for excellence in e-liquid production and flavor formulation. Moreover, the consistency and quality of their products are exemplary, and the company is excited to continue to work with them over the next decades.

Both Turning Point Brands and Pyxus anticipate the filing of their respective PMTAs before the May filing deadline.

Source Credit - https://www.prnewswire.com/news-releases/pyxus-signs-agreement-with-turning-point-brands-initiating-pmta-project-collaboration-300999171.html

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More

More News By Mateen Dalal

DealerSocket closes acquisition of Auto/Mate to offer innovative DMS
DealerSocket closes acquisition of Auto/Mate to offer innovative DMS
By Mateen Dalal

DealerSocket, a customer relationship management solutions provider, has recently completed the acquisition of DMS provider Auto/Mate to offer an all-in-one innovative software for their dealerships. Auto/Mate is a leading company that develops and m...

EU and U.S. to partner to counter Huawei’s dominance on next-gen 5G
EU and U.S. to partner to counter Huawei’s dominance on next-gen 5G
By Mateen Dalal

The European Union and the United States are likely to partner to counter the increasing dominance of Chinese tech giant, Huawei Technologies on next generation 5G telecommunications technology. However, this partnership will reportedly only come int...

CytoDyn files Phase 2 basket trial for cancer antagonist Leronlimab
CytoDyn files Phase 2 basket trial for cancer antagonist Leronlimab
By Mateen Dalal

CytoDyn Inc., announced that it has submitted a Phase 2 protocol with the U.S. Food and Drug Administration (FDA) for a basket trial under its cancer IND. The company can instantly start enrollment in this trial to offer therapy for around 22 various...